The Latest Phase 3 Data on Faricimab for DME

Caroline R. Baumal, MD

Show Description +

Caroline Baumal, MD, summarizes the efficacy, durability, and safety findings from YOSEMITE and RHINE.

Posted: 10/15/2021

Keywords:

Clinical Trials

•

retina-meeting-recap

Up Next

Name: The Latest Phase 3 Data on Faricimab for DME
Uploaded: 2021-10-15T17:52:39+00:00
Description: Caroline Baumal, MD, summarizes the efficacy, durability, and safety findings from YOSEMITE and RHINE.

Novel Sustained-Release Therapies for ME Due to RVO

Michael Singer, MD

Tackling Macular Edema with Suprachoroidal CLS-TA

Steven Yeh, MD

Efficacy of Pegcetacoplan in GA: Fellow Eye Comparison

Nathan Steinle, MD

Slowing GA Growth with C5 Inhibition

Jason Hsu, MD

Pearls for Preserving the Conjunctiva and Tenon’s Capsule With PDS Implantation

Veeral Sheth, MD

A Look at Fluid in Wet AMD Patients With the Port Delivery System

Arshad Khanani, MD

The Benefits of PPV for Visually Significant Floaters

Matthew Cunningham, MD

RGX-314 for Wet AMD: Phase 1/2a Results

Lejla Vajzovic, MD

Questions Remain for Pneumatic Vitreolysis for VMT

Calvin Mein, MD; and Clement Chan, MD

Universal Face Mask Use and Endophthalmitis Risk

Sunir Garg, MD

The Path to a Dry Retina in VIVID/VISTA

Rishi P. Singh, MD

Back to All Videos

The Latest Phase 3 Data on Faricimab for DME

Caroline R. Baumal, MD

Caroline Baumal, MD, summarizes the efficacy, durability, and safety findings from YOSEMITE and RHINE.

Posted: 10/15/2021

Keywords:

Clinical Trials

•

retina-meeting-recap

Please log in to leave a comment.

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

The Latest Phase 3 Data on Faricimab for DME

Up Next

The Latest Phase 3 Data on Faricimab for DME

More From ASRS: 2021 Coverage